XE9 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetModerate-to-low leverage and a sizable equity base provide financial flexibility while Xencor funds clinical development. This capital cushion can reduce balance-sheet pressure, support continued research investment, and improve resilience through lengthy biotechnology development cycles.
Settlement Improves Funding RunwayThe settlement provides substantial non-dilutive capital and extends the expected operating runway through 2028, giving management more time to advance programs and pursue partnerships. Retained ex-U.S. royalties also preserve an ongoing international revenue stream.
Differentiated Antibody PlatformThe XmAb platform offers a reusable antibody-engineering capability across oncology and autoimmune or inflammatory indications. Its ability to improve key antibody functions can support multiple internally developed and partnered candidates, creating potential leverage from platform innovation.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow indicates that Xencor remains far from self-funding. Continued investment in clinical programs may require additional capital or partnering proceeds, which can constrain strategic flexibility and increase funding dependence over the next several quarters.
Volatile Revenue And Weak ProfitabilityRevenue volatility makes financial performance difficult to forecast, while costs running well ahead of revenue show that the current pipeline has not yet produced dependable earnings power. This combination can prolong losses and limit the predictability of future operating results.
Loss Of Future U.S. RoyaltiesAlthough the settlement supplies immediate capital, ending future U.S. Ultomiris royalties removes a recurring domestic revenue source that had been expected through 2028. Xencor will therefore rely more heavily on pipeline progress, partnerships, and remaining international royalties.
Xencor News
XE9 FAQ
What was Xencor Inc’s price range in the past 12 months?
Currently, no data Available
What is Xencor Inc’s market cap?
Xencor Inc’s market cap is CHF1.55B.
When is Xencor Inc’s upcoming earnings report date?
Xencor Inc’s upcoming earnings report date is Nov 09, 2026 which is in 38 days.
How were Xencor Inc’s earnings last quarter?
Xencor Inc released its earnings results on Aug 05, 2026. The company reported -CHF0.241 earnings per share for the quarter, beating the consensus estimate of -CHF0.666 by CHF0.425.
Is Xencor Inc overvalued?
According to Wall Street analysts Xencor Inc’s price is currently Undervalued.
Does Xencor Inc pay dividends?
Xencor Inc does not currently pay dividends.
What is Xencor Inc’s EPS estimate?
Xencor Inc’s EPS estimate is -0.32.
How many shares outstanding does Xencor Inc have?
Currently, no data Available
What happened to Xencor Inc’s price movement after its last earnings report?
Xencor Inc reported an EPS of -CHF0.241 in its last earnings report, beating expectations of -CHF0.666. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Xencor Inc?
Currently, no hedge funds are holding shares in CH:XE9
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Xencor Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF26.69 (― Upside)
CHF26.69 (― Upside)
Blogger Sentiment
Bullish
CH:XE9 Sentiment 80%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
112.70%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-17.56%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Xencor Inc
Xencor Inc., a biopharmaceutical firm headquartered in Monrovia, California, and established in 1997, operates as a clinical-stage entity. Its central mission involves the discovery and sophisticated engineering of monoclonal antibody and cytokine therapeutics, primarily aimed at treating patients afflicted with cancer and autoimmune disorders. The company is associated with several notable therapies currently in use, such as Sotrovimab, which targets the SARS-CoV-2 virus; Ultomiris, prescribed for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi, indicated for individuals with relapsed or refractory diffuse large B-cell lymphoma. Xencor maintains a robust and diverse pipeline of drug candidates advancing through various clinical trial stages. In oncology, this includes Plamotamab, a tumor-targeted antibody, currently undergoing Phase I trials for non-Hodgkin lymphoma; Vudalimab, a bispecific antibody in Phase II for metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab, also in Phase II for neuroendocrine tumors. Further cancer-focused programs comprise XmAb306, XmAb104, and XmAb841, all in Phase I for selected solid tumors; AMG 509, in Phase I for prostate cancer; XmAb819, being developed for renal cell carcinoma; and a program involving Novartis XmAb. In the infectious disease arena, Xencor is progressing VIR-3434 through Phase II for hepatitis B virus infection; VIR-2482 in Phase 1/2 for influenza A; VIR-7832 in a Phase 1b/2a trial for mild-to-moderate COVID-19; and is involved in the Phase 2/3 NIH ACTIV-2 trial for COVID-19 with BMS-986414 + BMS-986413. Beyond these, the company is developing XmAb564, a Phase I candidate for autoimmune diseases; Obexelimab, also for autoimmune conditions; AIMab7195, designed to reduce IgE levels for allergic responses; and Xpro1595, an experimental treatment for Alzheimer's disease, mild cognitive impairment, and depression. Xencor also holds a licensing agreement with Caris Life Sciences.
XE9 Stock 12 Month Forecast
Average Price Target
―CytomX Therapeutics
―
AnaptysBio
―
Zymeworks
―
AbCellera Biologics
―
Inhibrx Biosciences Inc
―